Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

Item

http://www.wikidata.org/entity/Q33990855

Q33990855

about

Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Diagnosis and treatment of patients with thyroid cancer.Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.Evolving approaches to patients with advanced differentiated thyroid cancer Referral patterns for patients with high-risk thyroid cancer.Anaplastic Thyroid Carcinoma, Version 2.2015.RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer.Sorafenib and thyroid cancer.Vandetanib for the treatment of thyroid cancer: an update.New therapeutic options for advanced forms of thyroid cancer.Anti-angiogenic agent ramucirumab: meaningful or marginal?Sorafenib for the treatment of thyroid cancer: an updated review.Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.Personalization of targeted therapy in advanced thyroid cancer.Management of Invasive Differentiated Thyroid Cancer.Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma.Response to sorafenib treatment in advanced metastatic thyroid cancer.Advanced Thyroid Cancer Patients in Phase I Clinical Trials: Outcome Assessment and Literature Review.Refractory thyroid carcinoma: which systemic treatment to use?[Differentiated thyroid cancer].

P2860

Q26862841-F42CB96C-423B-49E5-8D33-FB7FF8E2CF5D Q28068710-237F6D21-21AF-4A9B-B384-1964B28FB69F Q33759426-7073EE05-9FB3-4614-8B53-43EE643FF6E2 Q35123709-E300FDF6-A59C-44D7-B539-EE75920CCFAB Q35195766-02707E1A-F8DD-4E5C-9B14-80A5242EAC0B Q35434188-E6862F2F-9C97-4747-AB3D-BE471075E956 Q35555583-0FF8FEA3-0426-402C-AA40-C755D4B27B85 Q35603183-EF2A064D-68E7-4248-B67D-0347E979EF08 Q35703167-5E7105AE-A772-4F0C-B21B-D3AB81019546 Q36060211-D4CF44B0-F03A-409C-9C88-1077ED832BB8 Q36508942-F02334D1-E879-489A-B2DB-D1FEBFA3736B Q36864736-789FB755-293E-4035-B4DB-FF2C6CFA7EB6 Q37104761-1139A786-BDAE-4B84-BFF8-25EFCCD60860 Q37179204-F3AFC441-64B6-496A-84E7-CB0B1706C17C Q37211774-D097AC43-C6D9-425A-A51B-4FAD06833297 Q37404382-1112BBAF-E172-41B7-90FA-1F00093E99CC Q37729290-F945029F-DEE8-44AC-801C-391F82A0732C Q38089099-90D093FB-A45A-4809-88F7-6BB8F38897C7 Q38118647-47F8E455-0934-462F-978F-FB8BE8336B30 Q38185691-AA6F5782-FB2B-4C0F-8807-DFF47E5AB8EC Q38192680-24F72172-8065-4C97-94EE-25F9552B8ECE Q38194159-8FB5CC96-4B41-4919-AA09-E4D65A316D6B Q38326036-6E6733DB-E782-447B-980F-EC665D05D5DE Q38368008-6D5463C6-FA52-4F05-8E0E-67430603505C Q38865611-1756BF8F-9EA4-4CD4-8454-9D86502B9EFD Q39323181-10D876AC-545A-45E2-86AB-9337DD4413B6 Q39934280-85EE8D62-7127-43F3-AF86-C8BCFB66CBFB Q40922523-B1602058-B525-4B6A-A766-00D447100BA7 Q41912985-CEDE0D88-25C8-4398-ADB0-23EF3D34C13C Q42279573-527C9264-DFC9-4BF3-992F-D1C44345B353 Q44062334-47FEAC2E-7FEC-4437-A593-F8DACCC9874B Q47123617-2F8B0E97-92A8-4678-9736-C43211A6C8C6 Q49335901-30710896-8F3D-4D86-AB8C-6416D1977500 Q54294298-0107007C-4DFA-4FA4-AC46-AF18212400DF

P2860

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

Item

http://www.wikidata.org/entity/Q33990855

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu